Despite the proven benefits of thrombolytic thera py in acute myocardial infarction, concern for its complicationq especially in patients misdiagnosed with myocardial infarction, has led to hesitancy in its use. Historical, clinical and electrocardiographic criteria were developed for enrolling patients with suspected acute myocardial infarction into thrombolytic trials by noncardiovascular specialists.
The incidence of misdiagnosis of myocardial infarction and the clinical outcomes when these criteria were used were evaluated for 1,267 consecutive patients given thrombolytic therapy. Twenty-five community hospitals and 7 interverr tional centers were the sites of enrollment. Most patients (62%) were enrolled from community hoe pitals. Criteria for thrombolytic therapy included: symptoms of acute myocardial infarction c6 hours but ~20 minutes, and not relieved by nitroglycerin; and S'kegment elevation ri mm in 2 contiguous leads or ST-segment depression of posterior myocardial infarction. Exclusion criteria reflecting ir+ creased risk of bleeding were used. A final diagnosis of myocardial infarction was based on creatinine kin-MB, electrocardiographic and ventriculographic evaluation. Acute myocardial infarction was misdiagnosed in 20 patients (1.4%; 95% confidence interval O&2.0%). These patients were demographically similar to those with acute myocardial infarction. All misdiagnosed patients survived; no significant adverse events occurred. Thus, in several clinical settings, a simple alge rithm with specific criteria was used for diw ing acute myocardial infarction and administering thrombolytic therapy. The inclusion criteria used in this study led to a low rate of misdiagnosis. (Am J Cardiol1993; 71:7-767) From T hrombolytic therapy is standard care in treating acute myocardial infarction in appropriately selected patients. l Well-controlled studies have proved its role in restoring vessel patency, improving left ventricular function and decreasing mortality.2-7 Despite these benefits, apprehension for its complications may limit its use. Infrequent but major bleeding complications8 raise concern, especially in patients with a mistaken diagnosis of acute myocardial infarction. Reports of the disastrous consequences of thrombolytic therapy to patients with aortic dissection or hemorrhagic pericarditis reinforce this issue.8,9
Given the high incidence and multiple etiologies of chest pain, and the need to administer thrombolytics early in the course of infarction, a mistaken diagnosis with inappropriate treatment could be extremely frequent. Misdiagnosis rates for acute myocardial infarction as great as 41% have been reported when electrocardiographic criteria are not used.'O However, electrocardiographic criteria alone may be insufficient. Lee et al" found that approximately 25% of patients who presented with acute chest pain and ST elevation did not have myocardial infarction.
In addition, most patients with suspected acute infarction are evaluated by primary care physicians without specialized training in cardiovascular medicine. The primary care physician may be less comfortable than a cardiologist in making the diagnosis and initiating thrombolytic therapy. Therefore, specific criteria for patient enrollment in community hospitals were developed by the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) study group (see later). These criteria were used in several different clinical settings, primarily by physicians who are not cardiovascular specialists. The purpose of this study was to evaluate the incidence and outcomes of misdiagnosis of acute myocardial infarction for patients given thrombolytic therapy in our series of 5 multicenter trials.
Ml3HODS
Criteria for patient selection: Patients enrolled in the TAMI-1,2 and 3, Intravenous Urokinase and TAMI-5 thrombolytic trials were evaluated for contirmation of myocardial infarction. The protocols for these studies, which were approved by institutional review boards at each facility and required informed consent for patient participation, were published previously.12-16 Patients were considered for inclusion if they had symptoms of acute myocardial infarction for <6 hours but >20 minutes after onset. Patients who had prompt relief of symptoms with sublingual nitroglycerin were excluded. Electrocardiographic criteria were the presence of ST-segment elevation 21 mm in 2 contiguous leads or ST depression consistent with posterior infarction, in the absence of previous Q-wave infarction in the same infarct-related artery distribution. Patients aged >75 years, and those with a recent history of cerebrovascular disease, surgery, trauma, bleeding or coronary artery bypass grafting were excluded. Patients with significant hypertension (>lSO mm Hg systolic or >llO mm Hg diastolic) or hypotension (~80 mm Hg systolic not responsive to fluid resuscitation) were also excluded. These spectic criteria were used in 25 community hospitals and 7 interventional centers to enroll 1,387 patients; a complete listing of these hospitals was presented previously.12 Determination of myocardial infarction:
The attending cardiologist at each interventional center determined the iinal diagnosis for each patient based on creatinine kinase (CK)-MB, electrocardiographic and ventriculographic evaluation in the setting of a compatible clinical event. Values for significant CK-MB elevation that were standard for each center were used and recorded prospectively. The entry electrocardiogram was sent to the ECG Coordinating Center at Duke University Medical Center for analysis. Angiographic data were used where appropriate (e.g., unstable angina was diagnosed if significant coronary artery stenosis was noted and if no increase in CK-MB was detected). Patients were identified in a prospective fashion by the diagnosis given during their hospitalization. In addition, the records for any patient with a coronary angiogram showing an infarct-related artery stenosis ~75% were reviewed for misdiagnosis of acute infarction.
All coronary angiograms were reviewed by the clinical stti at each institution in conjunction with the clinical diagnosis. Each coronary angiogram was then forwarded and independently evaluated at the University of Michigan Core Angiographic Laboratory. Left ventricular ejection fraction and the degree of coronary artery stenosis were assessed at the core laboratory as previously described.'*J7J8 The core laboratory values were used for data review and analysis.
Determination of clinical outcomes:
The major outcomes assessed in this study were death, nonhemorrhagic stroke, intracranial bleed, blood loss (needing transfusion of 22 units of packed red blood cells), sustained hypotension and vascular repair of a catheterization site. Patients were carefully monitored throughout hospitalization. Multiple data items were collected prospectively by research nurses during the patients' clinical courses. The findings were forwarded to the Biostatistical Coordinating Center at Duke University Medical Center for data entry and quality assurance. All major outcomes were checked against the medical record. In addition, any documentation of the use of cocaine or alcohol, the occurrence of cardiac tamponade, or any other complication related to receiving thrombolytic therapy in the misdiagnosed group was assessed by reviewing medical records retrospectively.
Data analysis: Data are expressed as mean ? 1 SD, and as 25th, 50th and 75th percentiles for each group. A binomial distribution of dichotomous events was assumed for determining confidence intervals.19 A chisquare test was used to compare misdiagnosis rates between referral centers and community hospitals.
RESULTS
Percentage of study group misdiagnosed with acute myocardial infarction: Of 1,387 patients enrolled, 20 (1.4%; 95% confidence interval 0.X-2.0%) had no evolutionary evidence of acute myocardial infarction despite entry in the trial. Nonischemic chest pain syndromes in conjunction with early repolarization were observed in 4 patients; 1 with probable esophageal spasm presented with inferior ST elevation. Pericarditis (n = 3), vasospasm (n = 3), hypertensive cardiomyopathy (n = 1) and unstable angina (n = 8) were the diagnoses for 15 patients. The rates of misdiagnosis for the 5 trials were as follows: 1% (4 of 386) for TAMI-1, 1.4% (1 of 147) for TAMI-2, 1.7% (3 of 175) for TAM13, 2.9% (3 of 102) for the Intravenous Urokinase trial, and 1.4% (8 of 577) for TAMI-5. Community hospitals enrolled 63% of patients. Fifteen misdiagnosed patients were in this subgroup, resulting in a misdiagnosis rate for community hospitals of 1.7% (15 of 874). The remaining 5 misdiagnosed patients were initially evaluated in 1 of 7 tertiary hospitals, resulting in a misdiagno- 784 THE AMERICAN JOURNAL OF CARDIOLOGY VOLUME 71 APRIL 1, 1993 sis rate for referral centers of 1% (5 of 513). The slight-group. The misdiagnosed group tended to be younger ly greater misdiagnosis rate for community hospitals and had a lower incidence of history of hypertension; was not statistically significant (p = 0.26). however, there were no differences for cardiovascular duration of chest pain before receiving thrombolytic therapy. Figure 1 shows electrocardiograms from patients given thrombolytic therapy and subsequently diagnosed with coronary vasospasm, pericarditis and early repolarization. On review of the 20 entry electrocardiograms for the misdiagnosed group, 11 (55%) did not fulfill the electrocardiographic criteria of 21 mm of ST elevation in 2 contiguous leads or ST depression consistent with posterior infarction, with absence of Q waves in the area of injury.
Coronary angiograms were obtained in 17 of 20 misdiagnosed patients (85%) and in 1,316 of 1,367 patients (96%) with acute infarction. No difference in left ventricular ejection fraction was observed between the 2 groups (acute infarction patients 51 + 12% vs misdiagnosed patients 48 IfI 14%; p = NS). In the misdiagnosed group, 8 patients had no coronary artery stenoses 250%; 3 had l-vessel disease, 3 had 2-vessel disease, and 3 patients had 3-vessel disease.
Retrospective review of the records of the misdiagnosed group revealed no evidence of cocaine use, alcohol intoxication or other substance abuse in the 20 patients.
Outcomes for patients Patients with acute infarction in this study had complication rates of 6% for death, 1.5% for nonhemorrhagic stroke, 1% for intracranial bleed, 17% for bleeding needing transfusion of 22 units of packed red blood cells, and 2% for surgical repair of the catheterization site; no patient in the misdiagnosed group (95% contidence interval 0 to 14%) had any of these complications. l9 No incidences of cardiac tamponade, aortic dissection, complications of central line placement, or other major iatrogenic complications were observed. One patient developed a large hematoma at a peripheral intravenous site, 2 developed transient hematuria after placement of a urethral catheter, and 1 experienced chills with administration of urokinase.
One patient in the misdiagnosed group with 3-vessel coronary artery disease developed refractory unstable angina and needed urgent coronary bypass surgery. This patient received 3 units of packed red blood cells in the perioperative period. Two other patients in the misdiagnosed group with unstable angina underwent angioplasty procedures without complication. Two additional patients eventually needed elective coronary bypass surgery.
DISCUSSION
The major findings of this study were as follows: (1) The incidence of misdiagnosis of acute myocardial infarction was quite low when specific historical, clinical and electrocardiographic criteria were used; and (2) the use of clinical and electrocardiographic criteria such as ours may reduce the risk of serious bleeding in patients who are misdiagnosed, no deaths or significant untoward events occurred.
Careful attention to the electrocardiogram is underscored in this study; 55% of patients (11 of 20) misdiagnosed had a nondiagnostic entry electrocardiogram. Tiials using more permissive criteria than those of this study for administering thrombolytic therapy have been completed. In Gruppo Italiano per lo Studio della Streptochinasi nell'Infarcto Miocardico (GISSI),5 patients were not excluded if a Q wave was observed in the area of injury; patients were also enrolled for ST depression in the limb leads. The misdiagnosis rate was 5.8%. The Anglo-Scandinavian Study of Early Thrombolysis (ASSET) enrolled 2,516 patients based on the clinical decision of the physician treating the patient, and the percentage of patients misdiagnosed was 10.5%.6 The Thrombolysis Early in Acute Heart Attack Trial (TEA-HAT)'O enrolled 352 patients with suspected acute infarction within 165 minutes of chest pain without requiring electrocardiographic criteria; a misdiagnosis rate of 41% was observed. Thus, in our study with the use of specific electrocardiographic criteria in addition to historical and clinical criteria, a misdiagnosis rate of 1.4% compares very favorably.
Did this lower incidence of mistaken diagnosis account for the absence of major adverse consequences in patients misdiagnosed for acute myocardial infarction? In ASSET, patients with suspected infarction were given recombinant tissue plasminogen activator; 5 aortic dissections from the cohort of 2,516 patients were recognized in the lirst 24 hours and were fatal within 48 hours, and 2 dissections were discovered later during the hospital stay.6,20 No aortic dissections were observed in our study. This could be due to the more restrictive electrocardiographic changes required. It could also be due to chance alone, with an incidence of aortic dissection in the United States of approximately 0.03% yearly.*l However, patients with aortic dissection may have clinical presentations imitating myocardial infarction,22 and the more specific criteria may have conferred a diagnostic and survival benefit. Furthermore, in ASSET, among patients in whom a nonischemic chest pain syndrome was finally diagnosed, those treated with thrombolytic therapy had a 9.5% mortality rate compared with 1.2% for those treated with placebo.9 Thus, the absence of more specific criteria may have contributed to patients with other conditions (e.g., pericarditis and gastrointestinal disease) receiving thrombolytic therapy and having adverse consequences.9,23-25
The small number of patients in the misdiagnosed group limits the ability to demonstrate absence of adverse effects. No major complication in 20 patients has a wide confidence interval (0 to 14%).19 A study with a larger number of misdiagnosed patients would give greater power to the analysis of complication rates. For example, at a power of 80% and alpha of 0.05, a total of 125 misdiagnosed patients would be needed to detect a 5% complication rate. The small number of misdiagnosed patients in our cohort weakens the ability to state that patients inappropriately given thrombolytic therapy using our inclusion criteria have no or few adverse outcomes. Studies with larger numbers of misdiagnosed patients will be able to better comment on complication rates, but will also need to be interpreted in regard to the inclusion criteria used (lax vs strict).
An issue in any study assessing misdiagnosed patients given thrombolytic therapy is that the treatment may abort a potential myocardial infarction by achieving clot lysis and reperfusion before myocardial necro-sis occurs. In this study, 20 patients had no evidence of acute myocardial infarction based on ventriculogram, cardiac enzymes and evolutionary changes in the electrocardiogram. Of these patients, 9 had underlying coronary artery disease at catheterization. Eight patients had normal coronary arteries or insignificant coronary artery disease. Three patients in the misdiagnosed group did not have catheterization. Thus 20 of 1,387 patients could have lysed thrombus before progression to infarction. All patients in this group survived, but the numbers are too small to make conclusions regarding the benefit of thrombolytic therapy to patients with unstable angina. No large, randomized, controlled trial has been reported to evaluate whether thrombolytic therapy is beneficial for patients with unstable angina.26
The role of thrombolytic therapy in the treatment of patients with acute myocardial infarction continues to develop. The criteria used for inclusion in this study may prove to be too restrictive. Cragg et al27 reviewed 1,471 patients with acute myocardial infarction who presented to a large, community-based hospital; only 230 (16%) were eligible for thrombolytic therapy under protocol criteria similar to those in our study. Lee et all' evaluated 7,734 patients presenting to the emergency wards of 3 university and 4 community hospitals; 1,118 were ultimately shown to have acute infarction. Of these patients, 41% would have mhilled electrocardiographic criteria similar to those used in our study. If other criteria were used (chest pain <6 hours and bleeding risk factors) this percentage would decrease to 25%.25 Many patients with acute infarction who do not f&ill the criteria of our study may benefit from thrombolytic therapy. The results from ISIS-24 suggest that infarcting patients may benefit from treatment with thrombolytic therapy up to 24 hours after the onset of chest pain. ISIS-2 also suggests that patients aged >75 years may have substantial benefit from thrombolytic therapy, with mortality in this group reduced from 13 to 9%.4,28 In ASSET, trends toward survival benefit were observed in all groups, including those who had normal electrocardiograms6 The results from on-going clinical trials, as well as future developments in biochemical tests and noninvasive modalities for early diagnosis, should better clarify which patients to treat with thrombolytic therapy in the setting of acute myocardial infarction. 
